Oncology

Alliance Cancer Specialists and IDEOlogy Health unite to bring the latest cancer research directly to community care teams, enhancing patient outcomes.

With investments exceeding $1B, PCI Pharma Services is expanding its US sterile manufacturing, tackling supply chain risks and boosting domestic production.

A UK firm's breakthrough blood test for early breast cancer detection joins a prestigious EU network, aiming to personalize treatment and redefine diagnostics.

With its AI-powered blood test nearing FDA review, DELFI Diagnostics adds a top biotech CFO to its board, signaling major commercial and IPO ambitions.

RedHill Biopharma flips a capital deficit to positive equity, driven by savvy partnerships for its drugs Talicia and Bekinda and a promising R&D pipeline.

In a key human trial, Sona Nanotech's heat-based therapy saw a 60% complete response in tumors for melanoma patients who had exhausted other options.

A new consultancy service combines decades of expertise with advanced analytics to tackle the billion-dollar problem of wasted drug supply in clinical trials.

With 65% of its medical tourism revenue from Indonesia, Malaysia is doubling down on its most vital market through strategic outreach and world-class care.

NerView Surgical's NerveSense™ wins FACIT's top award, spotlighting a growing ecosystem making Ontario a global leader in oncology innovation.

A novel alpha-radiation therapy, Alpha DaRT, begins European trials, offering a new path for pancreatic cancer patients with no other treatment options.

A novel RNA vaccine targeting hidden cancer antigens gets UK approval for a clinical trial, offering new hope for patients with hard-to-treat ovarian cancer.

Winning top awards, China's Fosun Health unveils a bold strategy to become the premier gateway for Southeast Asian patients seeking advanced medical care.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

A novel drug, NP137, shows unprecedented results in a Phase 1 trial, potentially making inoperable pancreatic tumors treatable and improving survival.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

A novel drug that targets the cellular environment of the MYC cancer protein, not the protein itself, shows major promise in preclinical studies.

A volunteer army and cutting-edge science converge this May to combat brain cancer, a disease with grim survival rates and a devastating toll on the young.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.